These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1921784)

  • 21. Sublingual apomorphine in treatment of Parkinson's disease: a review.
    Hislop J; Margolesky J; Shpiner DS
    Int J Neurosci; 2024 May; 134(5):474-480. PubMed ID: 35986574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
    Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease.
    Nasser A; Gomeni R; Ceresoli-Borroni G; Xie L; Busse GD; Melyan Z; Rubin J
    J Pharmacokinet Pharmacodyn; 2024 Aug; 51(4):385-393. PubMed ID: 38578533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement].
    Trenkwalder C; Boesch S; Ceballos-Baumann A; Dressler D; Eggert K; Gasser T; Honig H; Müller T; Reichmann H; Sieb JP; Storch A; Odin P; Poewe W
    Nervenarzt; 2008 Apr; 79(4):475-9. PubMed ID: 18210043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
    Hughes AJ; Bishop S; Kleedorfer B; Turjanski N; Fernandez W; Lees AJ; Stern GM
    Mov Disord; 1993 Apr; 8(2):165-70. PubMed ID: 8474483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes.
    Hui JS; Fox SH; Neeson W; Bhargava P; Pappert E; Blum D; Navia B;
    Parkinsonism Relat Disord; 2020 Oct; 79():110-116. PubMed ID: 32927285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Inhaled levodopa: from evidence to experience].
    Martínez-Castrillo JC; Pareés-Moreno I; López Sendón-Moreno JL; Pérez-Torre P; Fanjul S; Patiño-Patón A; García-Ribas G; Alonso-Cánovas A
    Rev Neurol; 2024 Jun; 78(S01):S1-S10. PubMed ID: 38916176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subcutaneous apomorphine in Parkinson's disease.
    Pollak P; Champay AS; Hommel M; Perret JE; Benabid AL
    J Neurol Neurosurg Psychiatry; 1989 Apr; 52(4):544. PubMed ID: 2738604
    [No Abstract]   [Full Text] [Related]  

  • 29. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC; Burguera JA
    Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sublingual apomorphine in the treatment of Parkinson's disease.
    Kassubek J; Jost WH; Schwarz J
    J Neural Transm (Vienna); 2024 Oct; 131(10):1209-1216. PubMed ID: 38743091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sublingual apomorphine (Kynmobi) for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Oct; 62(1609):165-166. PubMed ID: 33429410
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease.
    Langdon N; Malcolm PN; Parkes JD
    Clin Neuropharmacol; 1986; 9(5):440-7. PubMed ID: 3768866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.
    Deffond D; Durif F; Tournilhac M
    J Neurol Neurosurg Psychiatry; 1993 Jan; 56(1):101-3. PubMed ID: 8429309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subcutaneous apomorphine in the treatment of Parkinson's disease.
    Frankel JP; Lees AJ; Kempster PA; Stern GM
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):96-101. PubMed ID: 2313313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apomorphine in patients with Parkinson's disease.
    Muguet D; Broussolle E; Chazot G
    Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease.
    Ondo W; Hunter C; Almaguer M; Jankovic J
    Mov Disord; 1999 Jul; 14(4):664-8. PubMed ID: 10435505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients.
    Thijssen E; Tuk B; Cakici M; van Velze V; Klaassen E; Merkus F; van Laar T; Kremer P; Groeneveld GJ
    Clin Transl Sci; 2024 May; 17(5):e13796. PubMed ID: 38712716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.
    Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY
    Mov Disord; 1998 Sep; 13(5):782-7. PubMed ID: 9756146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
    Factor SA
    Neurology; 2004 Mar; 62(6 Suppl 4):S12-7. PubMed ID: 15037666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.